{"pmid":32489655,"pmcid":"PMC7242013","title":"Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID-19 Pandemic.","text":["Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID-19 Pandemic.","Clin Liver Dis (Hoboken)","Lau, George","Ward, John W","32489655"],"journal":"Clin Liver Dis (Hoboken)","authors":["Lau, George","Ward, John W"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489655","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cld.972","topics":["Prevention"],"weight":1,"_version_":1668623433604268032,"score":9.490897,"similar":[{"pmid":32447721,"title":"Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.","text":["Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.","BACKGROUND: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. AIMS: In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. METHODS: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. CONCLUSIONS: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.","Hepatol Int","Lau, George","Sharma, Manoj","32447721"],"abstract":["BACKGROUND: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. AIMS: In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. METHODS: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. CONCLUSIONS: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal."],"journal":"Hepatol Int","authors":["Lau, George","Sharma, Manoj"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447721","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s12072-020-10054-w","keywords":["aclf","apasl","cld","covid-19","ddlt","guidance","hepatology","immunosuppression","ldlt","liver injury"],"locations":["APASL","APASL"],"topics":["Prevention"],"weight":1,"_version_":1667698385972363264,"score":69.583855},{"pmid":32341229,"title":"Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic.","text":["Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic.","The World Health Organization (WHO), on March 11(th) 2020, upgraded the status of the novel coronavirus disease (COVID-19) from epidemic to pandemic. Over two million individuals have been infected with SARS-CoV-2, the virus causing COVID-19, and as of April, 14(th) 2020, there were over 5000 confirmed cases in Saudi Arabia (SA). Many countries, including SA, have imposed major restrictions on travel, and everyday life, and the implications of these necessary changes are being felt in liver transplant (LT) centers in SA. Concerns remain that there is an increased risk for individuals over 65 years of age, with underlying medical conditions, or for those who are immunocompromised. Therefore, the Saudi Association for the Study of Liver Diseases and Transplantation (SASLT) established an urgent task force to launch a statement that can be utilized by LT centers as a guidance in the management of patients with advanced liver disease from the time of LT listing to the post-operative care of transplanted patients.","Saudi J Gastroenterol","Al-Judaibi, Bandar","Almaghrabi, Reem","Alghamdi, Mohammed","Al-Hamoudi, Waleed K","AlQahtani, Mohammed","Abaalkhail, Faisal","Shagrani, Mohammed","Sanai, Faisal M","32341229"],"abstract":["The World Health Organization (WHO), on March 11(th) 2020, upgraded the status of the novel coronavirus disease (COVID-19) from epidemic to pandemic. Over two million individuals have been infected with SARS-CoV-2, the virus causing COVID-19, and as of April, 14(th) 2020, there were over 5000 confirmed cases in Saudi Arabia (SA). Many countries, including SA, have imposed major restrictions on travel, and everyday life, and the implications of these necessary changes are being felt in liver transplant (LT) centers in SA. Concerns remain that there is an increased risk for individuals over 65 years of age, with underlying medical conditions, or for those who are immunocompromised. Therefore, the Saudi Association for the Study of Liver Diseases and Transplantation (SASLT) established an urgent task force to launch a statement that can be utilized by LT centers as a guidance in the management of patients with advanced liver disease from the time of LT listing to the post-operative care of transplanted patients."],"journal":"Saudi J Gastroenterol","authors":["Al-Judaibi, Bandar","Almaghrabi, Reem","Alghamdi, Mohammed","Al-Hamoudi, Waleed K","AlQahtani, Mohammed","Abaalkhail, Faisal","Shagrani, Mohammed","Sanai, Faisal M"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341229","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.4103/sjg.SJG_131_20","keywords":["covid-19","cirrhosis","liver transplant"],"locations":["Saudi Arabia","Saudi"],"countries":["Saudi Arabia"],"countries_codes":["SAU|Saudi Arabia"],"topics":["Prevention"],"weight":1,"_version_":1666138495840681985,"score":69.34354},{"pmid":32407967,"title":"COVID-19: an overview of worldwide recommendations for management of patients with liver diseases or liver transplantation.","text":["COVID-19: an overview of worldwide recommendations for management of patients with liver diseases or liver transplantation.","Clin Gastroenterol Hepatol","Perazzo, Hugo","Piedade, Juliana","Castro, Rodolfo","Pinto, Laura","Veloso, Valdilea G","Grinsztejn, Beatriz","Pereira, Gustavo","Fernandes, Flavia F","32407967"],"journal":"Clin Gastroenterol Hepatol","authors":["Perazzo, Hugo","Piedade, Juliana","Castro, Rodolfo","Pinto, Laura","Veloso, Valdilea G","Grinsztejn, Beatriz","Pereira, Gustavo","Fernandes, Flavia F"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407967","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cgh.2020.04.074","topics":["Prevention"],"weight":1,"_version_":1666802845433724930,"score":67.15813},{"pmid":32482463,"title":"Telemedicine, COVID-19 and liver diseases: Revamping remote care initiatives in hepatology.","text":["Telemedicine, COVID-19 and liver diseases: Revamping remote care initiatives in hepatology.","Ann Hepatol","Arrese, Marco","32482463"],"journal":"Ann Hepatol","authors":["Arrese, Marco"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482463","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.aohep.2020.05.002","topics":["Prevention"],"weight":1,"_version_":1668532114723700736,"score":64.79098},{"pmid":32277387,"pmcid":"PMC7146012","title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-ncov","covid-19","liver transplantation","management"],"locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1666138491597094912,"score":62.739777}]}